Intensity Therapeutics to Present Data on Intratumoral Injection of INT230-6 at the Frontiers in Cancer Immunotherapy Symposium
14 mai 2019 07h35 HE
|
Intensity Therapeutics Inc
WESTPORT, Conn., May 14, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through...
Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer
17 avr. 2019 07h35 HE
|
Intensity Therapeutics Inc
WESTPORT, Conn., April 17, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers...
Intensity Therapeutics to Participate in Panel at 2019 BIO CEO & Investor Conference
05 févr. 2019 07h35 HE
|
Intensity Therapeutics Inc
WESTPORT, Conn., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase...
Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia
11 déc. 2018 07h35 HE
|
Intensity Therapeutics Inc
WESTPORT, Conn., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase...
Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
08 nov. 2018 07h35 HE
|
Intensity Therapeutics Inc
Intratumoral injections of INT230-6 were well tolerated with no drug-related serious adverse events or dose-limiting toxicity in Phase 1/2 clinical studyPreclinical research demonstrates drug...
Intensity Therapeutics Raises $6.5 Million in Series B Financing
02 nov. 2018 07h35 HE
|
Intensity Therapeutics Inc
Proceeds to enable advancement of lead product candidate INT230-6 into Phase 2 clinical development for solid tumors WESTPORT, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc.,...
Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors
22 oct. 2018 07h35 HE
|
Intensity Therapeutics Inc
Intratumoral injections of INT230-6 were well tolerated with no drug-related serious adverse events or dose-limiting toxicityIncreases in circulating CD8 and CD4 T-cells and evidence of abscopal...
Intensity Therapeutics to Present Preliminary Data from Clinical Study of INT230-6 at Upcoming Medical Conferences
17 oct. 2018 07h35 HE
|
Intensity Therapeutics Inc
Posters at European Society for Medical Oncology (ESMO) 2018 Congress and Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting to highlight safety of intratumoral INT230-6 in patients with...
Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists
22 oct. 2015 07h35 HE
|
Intensity Therapeutics Inc
Westport, CT, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell activating anti-cancer drug products, announced...